Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clozapine--pharmacokinetic investigations and biochemical effects in man.

Literature DB >> 2682731

Clozapine--pharmacokinetic investigations and biochemical effects in man.

Abstract

Clozapine with its unique pharmacological profile was investigated in different studies in order to elucidate its clinical-biochemical effects. Acute pharmacokinetic data showed a wide interindividual range with a mean halflife time of 6.0 h. The excretion pattern of catecholamines and their metabolites as well as hormone secretion were influenced in a different way. After 30 days of treatment, psychotic symptoms had markedly improved. However, only weak correlations were found to plasma levels. Side effects, such as sedation and orthostatic dysregulation, adapted and normalized during treatment. CSF-MHPG, CSF-5-HIAA decreased, CSF-HVA increased after 20 days of treatment indicating that the dopamine as well as the serotonin and noradrenaline systems are affected by Clozapine.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2682731 DOI： 10.1007/bf00442556

Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN： 0033-3158 Impact factor: 4.530

18 in total

1. [Artificial hibernation by pharmacodynamical and physical means].

Authors: H LABORIT; P HUGUENARD
Journal: Presse Med Date: 1951-10-13 Impact factor: 1.228

2. Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine.

Authors: R C Smith; J M Davis
Journal: Life Sci Date: 1976-09-01 Impact factor: 5.037

3. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors: L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal: Psychopharmacology (Berl) Date: 1989 Impact factor: 4.530

Review 4. Biochemical and behavioural properties of clozapine.

Authors: D M Coward; A Imperato; S Urwyler; T G White
Journal: Psychopharmacology (Berl) Date: 1989 Impact factor: 4.530

5. [Study on dopamine beta hydroxylase in serum].

Authors: E Markianos; I Nyström
Journal: Arzneimittelforschung Date: 1974-07

Review 6. Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics.

Authors: A Delini-Stula
Journal: Pharmacopsychiatry Date: 1986-07 Impact factor: 5.788

7. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.

Authors: D Pickar; R Labarca; M Linnoila; A Roy; D Hommer; D Everett; S M Paul
Journal: Science Date: 1984-08-31 Impact factor: 47.728

8. [Syndromes in psychiatric illnesses. A comparative investigation with two rating scales (IMPS and AMP-scale) (author's transl)].

Authors: W Mombour
Journal: Arch Psychiatr Nervenkr (1970) Date: 1974

9. [Pharmacological and neurochemical effects of clozapine (Leponex): new aspects in the drug therapy of schizophrenia].

Authors: H R Bürki; W Ruch; H Asper; M Baggiolini; G Stille
Journal: Schweiz Med Wochenschr Date: 1973-12-01

10. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons.

Authors: T H Hand; X T Hu; R Y Wang
Journal: Brain Res Date: 1987-07-14 Impact factor: 3.252

17 in total

1. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

Authors: Jose de Leon; Francisco J Diaz; Richard C Josiassen; George M Simpson
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-10 Impact factor: 5.270

Clozapine--pharmacokinetic investigations and biochemical effects in man.

1. [Artificial hibernation by pharmacodynamical and physical means].

2. Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine.

3. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Review 4. Biochemical and behavioural properties of clozapine.

5. [Study on dopamine beta hydroxylase in serum].

Review 6. Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics.

7. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.

8. [Syndromes in psychiatric illnesses. A comparative investigation with two rating scales (IMPS and AMP-scale) (author's transl)].

9. [Pharmacological and neurochemical effects of clozapine (Leponex): new aspects in the drug therapy of schizophrenia].

10. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons.

1. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

Review 2. Mechanisms of clozapine-induced agranulocytosis.

Review 3. Predictors and markers of clozapine response.

4. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Review 5. Will routine therapeutic drug monitoring have a place in clozapine therapy?

6. Effects of clozapine on CSF homovanillic acid in spasmodic torticollis.

7. Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women.

8. CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

Review 9. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Review 10. Pharmacokinetics and pharmacodynamics of clozapine.